“As a physician-scientist, the patients I’ve treated who haven’t made it are always in the back of my mind, moving my laboratory work forward,” says Michael Engel, MD, PhD. His research group studies the molecular details that lead to the development of childhood leukemias and then leverages that information to combat them.
"cancer research" News
Your body's metabolism is different from a cancer cell's metabolism. Researchers like graduate student Zhizhou Ye are studying how cancer cells rewire their metabolism to survive and grow. Understanding these processes in depth could lead to therapies that stop cancer's growth.
Volunteers are needed for a research study about quitting smoking. Participants will be compensated for their time and nicotine patches will be provided at no cost.
RNA modification is an area of cell biology few people have studied, and the idea of exploring the boundaries of the known world is what first attracted graduate student Archana Yerra to a career in science.
Our bodies fight cancer more than we really know, says Dr. Kenneth Grossmann. And, he adds, advances in medicine can help the immune system fight cancer even better.
Although sarcomas make up a small percentage of adult cancers and about 15 percent of childhood cancers, they are anything but small to the families they affect. The sarcoma program at Huntsman Cancer Institute is dedicated to finding better treatments and a cure for these cancers of the body’s connective tissues, bone, and muscles.
Governor Gary R. Herbert declared the week of June 19–24, 2017, as Cure Cancer Week in Utah. The proclamation comes during the week Huntsman Cancer Institute (HCI) at the University of Utah dedicates its major research expansion, the Primary Children’s and Families’ Cancer Research Center.
For Brain Tumor Awareness Month, Randy Jensen, MD, PhD, wants you to know something: “There is a lot of hope for patients with brain tumors.”
Mary Beckerle, PhD, testified before the United States House of Representatives Committee on Oversight and Government Reform on the impact of federally-funded cancer research.
Huntsman Cancer Institute researcher Andrew Hahn, MD, received the Conquer Cancer Foundation of ASCO Merit Award. The award recognizes young researchers who have made a significant impact to their field of study and promotes clinical cancer research by giving recipients the chance to present their findings at conferences.
Biomedical research helps develop safe and effective disease treatments for all citizens. The 21st Century Cures Act, signed into law in December 2016, includes $4.8 billion to fund research and drug development. The law includes funds for the “Cancer Moonshot,” which seeks to accelerate cancer research in the United States. Cancer researchers at HCI urge the community to continue to support biomedical research.
On September 7, 2016, National Cancer Institute (NCI) Acting Director Douglas Lowy, MD, accepted the recommendations of the Cancer Moonshot Blue Ribbon Panel (BRP) on a set of scientific approaches to accelerate progress in cancer research. An overview of the report was published in the journal Science.
When Kiera Jorgensen was diagnosed with cancer at the age of 19, she fought not only sarcoma, but also a deadly mystery that had loomed over her family for generations. Now years out of treatment, Kiera has answers and is conducting research to help families like hers better understand a rare genetic mutation.
People who are overweight or obese are at higher risk for more cancers than previously thought, says a report published in the New England Journal of Medicine August 25, 2016. The International Agency for Research on Cancer (IARC) brought together a group of 21 researchers from around the world to look at more than 1,000 studies linking excess body fat and cancer. Neli Ulrich, PhD, senior director of Population Sciences at Huntsman Cancer Institute (HCI), was a member of the group. Ulrich is a cancer researcher who studies lifestyle and biologic factors in cancer prevention and cancer prognosis.
Congratulations to Theresa Werner, MD, Huntsman Cancer Institute (HCI) investigator and University of Utah assistant professor of medicine, who received a 2016 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI). Dr. Werner serves as medical director of the HCI Clinical Trials Office and manages an extensive portfolio of cancer clinical studies.
Huntsman Cancer Institute (HCI) at the University of Utah participated in a national summit on the Cancer Moonshot initiative on June 29, 2016. The Cancer Moonshot Summits were organized at the request of Vice President Joe Biden, and more than 270 organizations hosted summits that brought together patients and survivors, researchers, physicians, advocates, philanthropists, and data and technology experts to brainstorm ways of speeding up progress in cancer prevention, diagnosis, treatment, and care over the next five years—and to ultimately end cancer as we know it.
The Cancer Moonshot Initiative, launched during President Barack Obama’s 2016 State of the Union address and headed by Vice President Joe Biden, is generating excitement and hope in the world of cancer research and care. Huntsman Cancer Institute at the University of Utah is playing an important role in these efforts.
You might not see us during your visit to Huntsman Cancer Institute (HCI), but we want to let you know that we are working hard in the Varley Lab in the HCI research building next door. We conduct research that improves the treatment and care of patients like you. We are a small group of dedicated young men and women who are developing new strategies to diagnose and treat breast and ovarian cancer.
For National Cancer Control Month, Bridget Grahmann, BS, and Yelena Wu, PhD, of The Wu Team at Huntsman Cancer Institute (HCI) explain what cancer control is and how it helps people with cancer as well as those who may never have it.
Clinical trials for some cancer patients may be the last, best hope for survival. A phase I trial is the first time a treatment is studied in people—usually a select number of patients who have not had success with other treatments. A rigorous process of approval takes place before doctors test these new therapies on patients for the first time.